Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo in relapsed or refractory advanced predominantly non-squamous NSCLC after 2 or 3 prior regimens
2008-006914-62Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sorafenib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bayer. Primary endpoint: overall survival. Started Feb 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006914-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006914-62.